Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclosporine and multiple sclerosis: the cons.

P Rudge1

  • 1National Hospital for Nervous Diseases, London, England.

Neurology
|July 1, 1988
PubMed
Summary

Cyclosporine A, a potent immunosuppressant, was investigated for multiple sclerosis (MS) treatment. Despite animal study promise, clinical trials showed limited efficacy and significant toxicity, leading to a recommendation against its use in MS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amyloid antibody therapy for early-stage Alzheimer's disease: a critical review of three recent trials.

Journal of neurology·2024
Same author

Genome-wide association study of behavioural and psychiatric features in human prion disease.

Translational psychiatry·2015
Same author

Subacute sclerosing panencephalitis: rapidly progressive cognitive decline in a young patient.

British journal of hospital medicine (London, England : 2005)·2013
Same author

Multiparameter MR imaging in the 6-OPRI variant of inherited prion disease.

AJNR. American journal of neuroradiology·2013
Same author

PRION-1 scales analysis supports use of functional outcome measures in prion disease.

Neurology·2011
Same author

Distinct neuropsychological profiles correspond to distribution of cortical thinning in inherited prion disease caused by insertional mutation.

Journal of neurology, neurosurgery, and psychiatry·2011

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease with unknown etiology.
  • Immunologic factors are implicated in MS pathogenesis.
  • Previous immunosuppressive therapies have shown limited success in managing MS.

Purpose of the Study:

  • To evaluate the efficacy and safety of Cyclosporine A (CsA) in treating multiple sclerosis (MS).
  • To determine if CsA, a potent immunosuppressant, could offer benefits in MS patients.

Main Methods:

  • Review of existing literature and studies on immunosuppressive therapies for MS.
  • Analysis of animal models (experimental allergic encephalomyelitis) and their relevance to MS.
  • Assessment of Cyclosporine A's therapeutic index and toxicity profile.

Main Results:

  • Animal studies showed disease suppression by CsA, but exacerbation upon drug cessation.
  • Clinical application in MS demonstrated marginal benefits with significant toxicity.
  • CsA exhibits a low therapeutic index, with effective doses causing toxicity and tolerated doses lacking efficacy.

Conclusions:

  • Cyclosporine A is not recommended for the treatment of multiple sclerosis (MS).
  • The drug's low therapeutic index and potential for exacerbation outweigh any perceived benefits.
  • Further research into MS immunopathogenesis is needed to develop effective therapies.

Related Experiment Videos